Oxford BioMedica (LSE:OXB) Land And Improvements : £0.00 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica Land And Improvements?

Oxford BioMedica's land and improvements for the quarter that ended in Dec. 2023 was £0.00 Mil.

Oxford BioMedica Land And Improvements Historical Data

The historical data trend for Oxford BioMedica's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica Land And Improvements Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Oxford BioMedica Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines